Double Primary Cancer of the Prostate and Urothelial Cancer: A Single Institution Experience
- PMID: 38793091
- PMCID: PMC11121936
- DOI: 10.3390/jpm14050510
Double Primary Cancer of the Prostate and Urothelial Cancer: A Single Institution Experience
Abstract
Prostate cancer (PCa) ranks as the second most common cancer in Japanese males, while bladder cancer (BC) holds the tenth spot. Among double urological cancers, the incidence of synchronous or metachronous BC and PCa is the highest. Reports on upper urinary tract (UUT) urothelial cancer (UC) in PCa patients are limited. Here, we present three cases of metachronous PCa and BC, with subsequent diagnosis of ureteral and renal pelvic cancer during the course of the disease. In the follow-up of patients with urological cancers, it is important to be aware not only of the progression of the initial cancer but also the potential development of a second cancer.
Keywords: bladder cancer; prostate cancer; ureteral cancer; urothelial cancer.
Conflict of interest statement
The authors have no conflicts of interest in the subject matter or materials discussed in this manuscript.
Figures




References
-
- Borzillo V., Scipilliti E., Pezzulla D., Serra M., Ametrano G., Quarto G., Perdona S., Rossetti S., Pignata S., Crispo A., et al. Stereotactic Body Radiotherapy with Cyberknife System for Low- and Intermediate-Risk Prostate Cancer: Clinical Outcomes and Toxicities Of CyPro Trial. Front. Oncol. 2023;13:1270498. doi: 10.3389/fonc.2023.1270498. - DOI - PMC - PubMed
-
- Clarke N., Wiechno P., Alekseev B., Sala N., Jones R., Kocak I., Chiuri V.E., Jassem J., Fléchon A., Redfern C., et al. Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. Lancet Oncol. 2018;19:975–986. doi: 10.1016/S1470-2045(18)30365-6. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources